Meeting Coverage
>
TCT
—
Stent-related events plateaued 6 months after DynamX implant
by
Nicole Lou, Senior Staff Writer, MedPage Today
October 28, 2024
For percutaneous coronary intervention (PCI) on de novo lesions, the DynamX bioadaptor not only matched drug-eluting stents (DES) in early performance but seemed to keep stent-related events from accruing after 6 months, according to an interim analysis from INFINITY-SWEDEHEART.
In this randomized trial, the novel bioadaptor met criteria for noninferiority in terms of target lesion failure (TLF) at 1 year, a composite endpoint counting cardiovascular death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization (2.35% vs 2.77% with DES, P
Information contained on this page is provided by an independent third-party content provider. This website makes no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact editor @americanfork.business
